---
title: "Neusoft (600718): Won the procurement project of the Drug Evaluation Center of the National Medical Products Administration, with a winning amount of 2.34 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286889862.md"
description: "Neusoft Group (600718) won the bid for the procurement project of the Drug Evaluation Center of the National Medical Products Administration, with an amount of 2.34 million yuan. The operating revenue for 2024 is 11.56 billion yuan, with a growth rate of 9.64%, and the net profit is 63 million yuan, a decrease of 14.70%. In the first half of 2025, the operating revenue is 4.689 billion yuan, with a growth rate of 9.08%, and the net profit is 56 million yuan, a decrease of 42.75%"
datetime: "2026-05-19T09:56:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286889862.md)
  - [en](https://longbridge.com/en/news/286889862.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286889862.md)
---

# Neusoft (600718): Won the procurement project of the Drug Evaluation Center of the National Medical Products Administration, with a winning amount of 2.34 million yuan

According to Tongbi Finance, data from Qichacha shows that, based on the "Announcement of Winning Bids for the Procurement Project of Safety and Office Products for the Main Terminal of the Drug Review Center of the National Medical Products Administration (Second Round)," Neusoft Corporation announced on May 19, 2026, that it won the bid for the procurement project of the Drug Review Center of the National Medical Products Administration, with a winning amount of 2.34 million yuan.

Related listed company: Neusoft Corporation (600718.SH)

_Tongbi Finance Tip:_

_Neusoft Corporation (600718.SH) had an operating revenue of 11.56 billion yuan in 2024, with a revenue growth rate of 9.64%. The net profit attributable to the parent company was 63 million yuan, with a net profit growth rate of -14.70%, and a return on equity of 0.66%._

_In the first half of 2025, the company's operating revenue was 4.689 billion yuan, with a revenue growth rate of 9.08%. The net profit attributable to the parent company was 56 million yuan, with a net profit growth rate of -42.75%._

_Currently, the company belongs to the information technology industry, with main product types including ERP software, firewall software, software outsourcing services, and industry-specific software. The 2024 report shows the main composition of its business as self-developed software, products, and services (including medical equipment and Xikang): 83.94%; system integration: 14.37%; property advertising: 1.69%._

### Related Stocks

- [600718.CN](https://longbridge.com/en/quote/600718.CN.md)

## Related News & Research

- [03:43 ETNeusoft and HERE Deepen Strategic Collaboration to Forge an AI-Powered, One-Stop Intelligent Mobility Solution](https://longbridge.com/en/news/284334890.md)
- [The washout in software stocks has been played out, expert says](https://longbridge.com/en/news/288324011.md)
- [SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools | DHR Stock News](https://longbridge.com/en/news/288312158.md)
- [Palantir vs. Snowflake: Only 1 AI Software Stock Looks Strong for the Next Decade](https://longbridge.com/en/news/288060771.md)
- [SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations | DHR Stock News](https://longbridge.com/en/news/288312155.md)